NYSEAMERICAN:AIM AIM ImmunoTech Q2 2026 Earnings Results & Report $0.18 +0.00 (+0.22%) Closing price 04:10 PM EasternExtended Trading$0.18 0.00 (-0.56%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. AIM ImmunoTech reported Q2 2026 earnings on August 7, 2026. The company reported EPS of -$0.43, while revenue was $0.03 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 7, 2026TimeAfter Market ClosesConference Call7:00 AM ET AIM ImmunoTech EPS ResultsActual EPS-$0.43Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAIM ImmunoTech Revenue ResultsActual Revenue$0.03 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) AIM ImmunoTech Q2 2026 Earnings FAQ Did AIM ImmunoTech beat earnings estimates for Q2 2026? AIM ImmunoTech (NYSEAMERICAN:AIM) reported earnings of -$0.43 per share for Q2 2026. The report was announced on Friday, August 7, 2026. What was AIM ImmunoTech's revenue for Q2 2026? AIM ImmunoTech reported revenue of $0.03 million for Q2 2026. AIM ImmunoTech Earnings HeadlinesAIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysOctober 7 at 12:36 PM | finance.yahoo.comAIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysOctober 7 at 9:14 AM | globenewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 9 at 1:00 AM | Stansberry Research (Ad)Aim Immunotech Inc. Highlights Recent Media Coverage of Ampligen?S Broad-Spectrum Antiviral and Biodefense PotentialOctober 6 at 3:09 PM | marketscreener.comMAIM ImmunoTech Highlights Recent Media Coverage of Ampligen's Broad-Spectrum Antiviral and Biodefense PotentialOctober 6 at 3:09 PM | marketscreener.comMAIM ImmunoTech Highlights Ampligen's Broad-Spectrum Antiviral PotentialOctober 5, 2026 | rttnews.comSee More AIM ImmunoTech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AIM ImmunoTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AIM ImmunoTech and other key companies, straight to your email. Email Address About AIM ImmunoTechAIM ImmunoTech (NYSEAMERICAN:AIM) is a clinical-stage immuno-pharmaceutical company focused on developing therapies that activate and regulate the immune system. The company’s research programs target cancer, viral diseases and other conditions in which immune-system activity may play a role in disease progression or treatment response. AIM’s principal investigational product is Ampligen (rintatolimod), a double-stranded RNA-based immune modulator designed to stimulate antiviral and antitumor immune responses. Ampligen has been studied in conditions including myalgic encephalomyelitis/chronic fatigue syndrome, various cancers and viral infections. It remains an investigational therapy and has not received broad U.S. marketing approval. The company also markets Alferon N Injection, a natural human leukocyte interferon product approved in the United States for the treatment of refractory or recurring external genital warts in adults. AIM ImmunoTech was formerly known as Hemispherx Biopharma and adopted its current name in 2019. The company is headquartered in Ocala, Florida, and is led by Chief Executive Officer Thomas K. Equels. Its activities include clinical development, regulatory work and collaborations intended to advance its immune-modulating product candidates in the United States and international markets.View AIM ImmunoTech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
